We are live on
!
Find out more
SI
Sofinnova Investments Portfolio holdings
AUM
$1.93B
1-Year Est. Return
134.74%
This Fund
S&P 500
This Quarter
Est. Return
-20.83%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$803M
AUM Growth
-$319M
(-28%)
Cap. Flow
-$26.3M
Cap. Flow
% of AUM
-3.28%
Top 10 Holdings %
Top 10 Hldgs %
60.78%
Holding
78
New
17
Increased
17
Reduced
12
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NCNA
NuCana
NCNA
|
+$28.4M |
| 2 |
Gilead Sciences
GILD
|
+$14.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$13.4M |
| 4 |
Incyte
INCY
|
+$12.2M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$9.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$61.6M |
| 2 |
AGN
Allergan plc
AGN
|
+$18.3M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$9.09M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$7.67M |
| 5 |
Exelixis
EXEL
|
+$7.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.64% |
| 2 | Miscellaneous | 5.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$17.1B
| $93.9M | 11.7% |
1,498,538
-980,976
| -40% | -$61.6M |
|
|
AMRN
2
Amarin Corp
AMRN
$304M
| $70.9M | 8.83% |
260,415
| – | – |
|
|
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $60.1M | 7.49% |
4,749,623
| – | – |
|
|
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $55.8M | 6.95% |
2,038,208
-20,938
| -1% | -$540K |
|
5
Natera
NTRA
$47.6B
| $43.3M | 5.39% |
3,100,560
| – | – |
|
|
YMAB
6
DELISTED
Y-mAbs Therapeutics
YMAB
| $42.8M | 5.33% |
2,104,278
| – | – |
|
|
NCNA
7
NuCana
NCNA
$5.7M
| $32.9M | 4.09% |
453
+320
| +241% | +$28.4M |
|
|
MRUS
8
DELISTED
Merus
MRUS
| $27.5M | 3.42% |
1,961,039
| – | – |
|
9
Coherus Oncology
CHRS
$204M
| $26M | 3.23% |
2,868,221
| – | – |
|
10
Kiniksa Pharmaceuticals
KNSA
$6.13B
| $25.9M | 3.23% |
922,700
| – | – |
|
|
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
| $19.9M | 2.48% |
933,640
| – | – |
|
|
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $18.8M | 2.35% |
481,270
| – | – |
|
13
Sanofi
SNY
$103B
| $14.2M | 1.77% |
327,175
-85,571
| -21% | -$3.77M |
|
14
Aclaris Therapeutics
ACRS
$818M
| $14.1M | 1.76% |
1,911,573
+372,093
| +24% | +$3.84M |
|
|
15
Gilead Sciences
GILD
$181B
| $13.3M | 1.66% |
+213,331
| New | +$14.9M |
|
16
AstraZeneca
AZN
$243B
| $12M | 1.5% |
158,164
+37,860
| +31% | +$2.96M |
|
|
17
Incyte
INCY
$25.5B
| $12M | 1.49% |
+188,497
| New | +$12.2M |
|
|
18
BioMarin Pharmaceuticals
BMRN
$12.5B
| $12M | 1.49% |
+140,542
| New | +$13.4M |
|
|
TSRO
19
DELISTED
TESARO, Inc.
TSRO
| $9.97M | 1.24% |
134,297
-89,378
| -40% | -$4.3M |
|
20
Heron Therapeutics
HRTX
$63.2M
| $9.33M | 1.16% |
359,713
+64,124
| +22% | +$1.76M |
|
|
RETA
21
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $8.86M | 1.1% |
+157,984
| New | +$9.65M |
|
|
ITRM
22
DELISTED
Iterum Therapeutics
ITRM
| $8.65M | 1.08% |
115,101
| – | – |
|
23
Rigel Pharmaceuticals
RIGL
$882M
| $7.78M | 0.97% |
338,217
+12,124
| +4% | +$342K |
|
24
Xencor
XNCR
$1.85B
| $7.22M | 0.9% |
+199,682
| New | +$7.33M |
|
|
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
| $6.46M | 0.81% |
674,636
+228,667
| +51% | +$2.51M |
|
Similar funds
GIA
EK
CTI
SI
P3I
TCM
MCWS
SWM
Sofinnova Investments's Q4 2018 Portfolio in Review
As of Q4 2018, Sofinnova Investments held 78 positions worth $803M, down 28% from $1.12B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Sofinnova Investments withdrew a net $26.3M in Q4 2018, closing 19 positions and reducing 12 holdings. Its most notable exit was Allergan plc, an estimated $18.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Miscellaneous.
Against the trend, Sofinnova Investments opened a new position in Gilead Sciences worth $13.3M.
- Sofinnova Investments's largest Q4 2018 buy was Gilead Sciences: 213,331 shares worth $13.3M.
- Sofinnova Investments added most to NuCana in Q4 2018, an estimated $28.4M increase.
- Sofinnova Investments's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $61.6M.
- Sofinnova Investments fully exited Allergan plc in Q4 2018, selling an estimated $18.3M.
- Sofinnova Investments's ten largest holdings make up 61% of its $803M portfolio in Q4 2018.
- Sofinnova Investments opened 17 new positions and closed 19 in Q4 2018.
- Sofinnova Investments's portfolio value fell 28% quarter-over-quarter to $803M.
Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.